Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Operating Expenses (2018 - 2026)

DiaMedica Therapeutics filings provide 9 years of Operating Expenses readings, the most recent being $10.5 million for Q1 2026.

  • Quarterly Operating Expenses rose 28.71% to $10.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $36.7 million through Mar 2026, up 26.31% year-over-year, with the annual reading at $34.4 million for FY2025, 28.92% up from the prior year.
  • Operating Expenses hit $10.5 million in Q1 2026 for DiaMedica Therapeutics, up from $9.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $10.5 million in Q1 2026 and bottomed at $3.1 million in Q3 2022.
  • Average Operating Expenses over 5 years is $6.3 million, with a median of $5.7 million recorded in 2024.
  • The largest annual shift saw Operating Expenses dropped 8.43% in 2022 before it soared 64.87% in 2023.
  • DiaMedica Therapeutics' Operating Expenses stood at $4.0 million in 2022, then surged by 47.19% to $5.8 million in 2023, then skyrocketed by 43.96% to $8.4 million in 2024, then grew by 9.43% to $9.2 million in 2025, then increased by 13.77% to $10.5 million in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Operating Expenses are $10.5 million (Q1 2026), $9.2 million (Q4 2025), and $9.0 million (Q3 2025).